Omega Therapeutics Inc Defensive Interval Ratio
Omega Therapeutics Inc defensive interval ratio. Omega Therapeutics Inc (OMGA) has a Defensive Interval Ratio of 7 days as of September 2024. Defensive assets of $486.00K (cash $-, short-term investments $0.00, receivables $486.00K) cover 7 days of daily cash needs of $66.23K/day. See Omega Therapeutics Inc (OMGA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Defensive Interval Ratio of Omega Therapeutics Inc (2019–2023)
Defensive interval ratio of Omega Therapeutics Inc from 2019 to 2023. This chart shows how Omega Therapeutics Inc's Defensive Interval Ratio has evolved across 5 annual periods from 2019 to 2023. As of September 2024, the ratio stands at 7 days, meaning defensive assets of $486.00K can fund 7 days of operations without new revenue. Check Omega Therapeutics Inc (OMGA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Omega Therapeutics Inc Defensive Interval Ratio by Year (2019–2023)
Omega Therapeutics Inc defensive interval ratio by year from 2019 to 2023. The table below presents the year-by-year Defensive Interval Ratio for Omega Therapeutics Inc from 2019 to 2023, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For the complete balance sheet picture, see total assets of Omega Therapeutics Inc.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2023 | 163 days | $11.97 Million | $73.44K/day | $- | $4.99 Million | ▼ -765 days |
| 2022 | 928 days | $55.86 Million | $60.18K/day | $- | $54.06 Million | ▼ -271 days |
| 2021 | 1199 days | $39.37 Million | $32.83K/day | $- | $38.84 Million | ▲ +1190 days |
| 2020 | 9 days | $193.00K | $21.09K/day | $- | $0.00 | ▲ +8 days |
| 2019 | 1 days | $5.00K | $6.10K/day | $- | $- | — |